Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.31 |
| ▸ | PI4KA | P42356 | 3/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536971 | 0.67 | LRRK2 (0.31) | LRRK2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2255360 | 0.64 | DAPK3 (0.30) | RETDAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL2254848 | 0.64 | DAPK3 (0.33) | RETDAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL14793616 | 0.64 | DAPK3 (0.30) | RETDAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL2260102 | 0.61 | PDE5A (0.32) | — | |
| SCHEMBL14793625 | 0.60 | — | — | |
| SCHEMBL6055417 | 0.57 | PNP (0.41) | XDHLMNA | |
| SCHEMBL8553010 | 0.57 | RET (0.34) | LRRK2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1718947 | 0.57 | — | — | |
| SCHEMBL18520344 | 0.57 | RET (0.36) | LRRK2PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | claimed |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | ISMAILI HICHAM MOULAY ALAOUI (CA) | 2004-12-09 | — | — | US | claimed |
| WO-2004106350-A1 | NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS | BIOCRYST PHARMACEUTICAL, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | claimed |
| US-20040229839-A1 | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | US | claimed |
| US-6784161-B2 | VIRICIDES FOR HEPATITIS C | BIOCHEM PHARMA, INC. (CA) | 2004-08-31 | — | — | US | claimed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | claimed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | claimed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | claimed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | claimed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-0236935-A2 | Carboxylic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |
| EP-0719273-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0521463-A2 | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-01-07 | — | — | EP | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | LRRK2 4433/4885PI4KA 663/4885PI4K2B 1051/4885 |
| US-20040229839-A1 | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, RNGTT, RNMT | LRRK2 3804/4885PI4KA 4097/4885PI4K2B 4251/4885 |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | LRRK2 2817/4885PI4KA 4247/4885PI4K2B 4249/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | LRRK2 2817/4885PI4KA 4247/4885PI4K2B 4249/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | LRRK2 4433/4885PI4KA 663/4885PI4K2B 1051/4885 |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | LRRK2 4380/4885PI4KA 1991/4885PI4K2B 2162/4885 |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | LRRK2 4433/4885PI4KA 663/4885PI4K2B 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.